Coagulopathy induced by continuous infusion of high doses of human lymphoblastoid interferon.
Seven patients with myeloblastic leukemia were treated for 10 days with high-dose (15 or 30 million units/m2/day), human lymphoblastoid interferon (Wellferon) by continuous iv infusion. All patients developed prolonged activated partial thromboplastin time, and four developed prolonged prothrombin time. Factor assays demonstrated low levels of II, VII, IX, X, and XII. Coagulation abnormalities improved after discontinuation of interferon therapy.
D000293:Adolescent; D000328:Adult; D001778:Blood Coagulation Disorders / Q000097:blood / Q000209:etiology*; D001779:Blood Coagulation Factors / Q000032:analysis; D001780:Blood Coagulation Tests; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D006801:Humans; D007223:Infant; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D012189:Retrospective Studies
D001779:Blood Coagulation Factors; D007370:Interferon Type I